Conditional neural knockout of the adenosine A2A receptor and pharmacological A2A antagonism reduce pilocarpine-induced tremulous jaw movements: Studies with a mouse model of parkinsonian tremor

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 972-977

  Salamone, John D ^a   Collins Praino, Lyndsey E ^a   Pardo, Marta ^a,b   Podurgiel, Samantha J ^a   Baqi, Younis ^c   Müller, Christa E ^c   Schwarzschild, Michael A ^d   Correa, Mercè ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITAT JAUME I   (Spain)

^c UNIVERSITY OF BONN   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acetylcholine; Motor; Muscarinic receptor; Parkinson's disease; Parkinsonism; Striatum

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; PILOCARPINE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEASIBILITY STUDY; JAW DISEASE; JAW MOVEMENT; MALE; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; TEMPOROMANDIBULAR JOINT; TREATMENT RESPONSE; TREMOR;

ACETYLCHOLINE; MOTOR; MUSCARINIC RECEPTOR; PARKINSON'S DISEASE; PARKINSONISM; STRIATUM;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; JAW; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PILOCARPINE; PRODRUGS; RANDOM ALLOCATION; RECEPTOR, ADENOSINE A2A; TREMOR; XANTHINES;

EID: 84881664456     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.08.004     Document Type: Article

References (33)

1. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61:293-296.
2. Bastia E., Xu Y.H., Scibelli A.C., Day Y.J., Linden J., Chen J.F., Schwarzschild M.A. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 2005, 30:891-900.
3. Betz A.J., McLaughlin P.J., Burgos M., Weber S.M., Salamone J.D. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology 2007, 194:347-359.
4. 2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 2009, 163:97-108.
5. Bezchlibnyk-Butler K.Z., Remington G.J. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can. J. Psychiat 1994, 39:74-84.
6. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M., Beilstein M.A., Hacket E., Fink J.S., Low M.J., Ongini E., Schwarzschild M.A. The role of the D2 dopamine receptor (D2R) in A2A adenenosine-receptor (A2aR) mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice. Proc. Natl. Acad. Sci. 2001, 98:1970-1975.
7. 2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology 2003, 61:S74-S81.
8. 1 antagonist DPCPX: possible relevance for drug-induced parkinsonism. Pharmacol. Biochem. Behav. 2010, 94:561-569.
9. Collins L.E., Paul N.E., Abbas S.F., Leser C.E., Galtieri D.J., Chrobak J.J., Baqi Y., Muller C.E., Salamone J.D. Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. Pharmacol. Biochem. Behav. 2011, 99:414-422.
10. Collins-Praino L.E., Paul N.E., Rychalsky K.L., Hinman J.R., Chrobak J.J., Senatus P.B., Salamone J.D. Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Front. Syst. Neurosci. 2011, 5:49.
11. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav. Brain Res. 2004, 148:47-54.
12. Deuschl G., Raethjen J., Lindemann M., Krack P. The pathophysiology of tremor. A review. Muscle Nerve 2001, 24:716-735.
13. 2A receptor knockout mice are partially protected against drug-induced catalepsy. Neuroreport 2001, 12:983-986.
14. Finn M., Jassen A., Baskin P., Salamone J.D. Tremulous characteristic of vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol. Biochem. Behav. 1997, 57:243-249.
15. 2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des. 2008, 14:1468-1474.
16. Ishiwari K., Betz A., Weber S., Felsted J., Salamone J.D. Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacol. Biochem. Behav. 2005, 80:351-362.
17. Jicha G., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible model of parkinsonian symptoms. J. Neurosci. 1991, 11:3822-3829.
18. 2A receptors in the shell of the nucleus accumbens. J. Neurosci. 2011, 31:10067-10075.
19. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 2008, 63:295-302.
20. Miwa H., Kubo T., Suzuki A., Kondo T. Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. Parkinsonism Relat. Disord. 2009, 15:30-35.
21. 2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice. Neuropharmacology 2012, 62:2068-2077.
22. Pinna A., Schintu N., Simola N., Volpini R., Pontis S., Cristalli G., Morelli M. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 2010, 58:613-623.
23. 2A adenosine receptor modulates the reinforcing efficacy and neurotoxicity of MDMA. J. Psychopharmacol. 2011, 25:550-564.
24. Salamone J.D., Lalies M.D., Channell S.L., Iversen S.D. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharm. 1986, 88:467-471.
25. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol. 1998, 56:591-611.
26. Salamone J.D., Correa M., Carlson B., Wisniecki A., Mayorga A., Nisenbaum E., Nisenbaum L., Felder C. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism. Life Sci. 2001, 68:2579-2584.
27. Salamone J.D., Carlson B.B., Rios C., Lentini E., Correa M., Wisniecki A., Betz A. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav. Brain Res. 2005, 156:173-179.
28. 2A antagonists: implications for parkinsonism. Front. Biosci. 2008, 13:3594-3605.
29. 2A receptors in Parkinson's disease. Trends Neurosci. 2006, 29:647-654.
30. 2A receptors anatagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp. Neurol. 2004, 189:182-188.
31. Song I.U., Kim J.S., Ryu S.Y., Lee S.B., An J.Y., Lee K.S. Donepezil-induced jaw tremor. Parkinson. Rel. Disord. 2008, 14:584-585.
32. Wei C.J., Li W., Chen J.F. Normal and abnormal functions of adenosine receptors in the central nervous system as revealed by genetic knockout studies. Biochim. Biophys. Acta 2011, 1808:1358-1379.
33. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 2008, 63:338-346.